MRx1299 has a different mechanism of action to MRx0518 and as such may be suitable for the treatment of different types of cancer. Alex Stevenson, 4D’s Chief Scientific Officer, commented “The identification of our new Live Biotherapeutic candidate, MRx1299, strengthens our leading oncology portfolio and expands the scope of oncology indications for our Live Biotherapeutics. Research presented at the conference indicates a role for additional host receptors, including TLR9, in mediating the immuno-stimulatory effects of MRx0518. 2019), demonstrating that the bacterial flagellin protein, FliC, strongly activates immunostimulatory NF-κB signalling, via the TLR5 receptor. The Company has previously published data on the mechanism of action of MRx0518 ( Lauté-Caly et al. New data presented demonstrates the ability of orally administered MRx0518 to modulate the frequency of immune cell populations with anti-tumour activity in the gastrointestinal tract, systemically and in the tumour microenvironment, acting through signalling pathways known to drive anti-cancer immunity. MRx0518, the Company’s lead Live Biotherapeutic candidate in oncology, induces strong innate and adaptive immune responses in vitro and in vivo.
Treatment with MRx1299 and its metabolites gives cytotoxic T lymphocytes the ability to reduce tumour growth in preclinical cancer models. MRx1299 is a second-generation Live Biotherapeutic identified by 4D’s MicroRx® discovery platform.One of the target host pathways identified for this Live Biotherapeutic is its potent histone deacetylase (HDAC) inhibition mediated by bacterial short-chain fatty acids (SCFAs).HDAC inhibition is thought to have multiple modes of anti-cancer activity, acting on both tumour and immune cells.
#4d pharma oncology update
A clinical progress update on MRx0518 was also provided by 4D’s Chief Scientific Officer, Alex Stevenson. New preclinical data on the Company’s oncology candidates, MRx0518 and MRx1299, were presented at 1 st Microbiome Movement Oncology Response Summit in Boston, USA by Research Director Imke Mulder.
We are excited to work with MSD and look forward to collaborating on this project.Second-generation Live Biotherapeutic Identified and Mechanistic Data on MRx0518 and MRx1299 PresentedĤD pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on its oncology programmes. The phase I study will evaluate safety, tolerability and preliminary clinical benefit of the combination of KEYTRUDA with MRx0518 in patients who progressed on prior PD-1 inhibitor therapy with renal, bladder, melanoma and non-small cell lung cancer.ĭuncan Peyton, founder and Chief Executive Officer of 4D, commented: “At 4D we believe there is strong scientific rationale for evaluating our lead oncology programme MRx0518, in combination with a checkpoint inhibitor. MRx0518, 4D’s lead oncology programme, has shown therapeutic potential in a variety of tumour types in pre-clinical models and has the potential for synergy in combination with checkpoint inhibitor therapies.
#4d pharma oncology trial
4D pharma plc (AIM: DDDD), a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products, today announced an agreement with a subsidiary of MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) to conduct a clinical trial evaluating the combination of KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by MSD, and 4D’s live biotherapeutic candidate MRx0518 in patients with solid tumours.
0 kommentar(er)
